
Amrutanjan Health (AMRUTANJAN) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
1.4B
Gross Profit
664.2M
49.05%
Operating Income
160.8M
11.87%
Net Income
151.8M
11.21%
Balance Sheet Metrics
Total Assets
4.2B
Total Liabilities
947.7M
Shareholders Equity
3.3B
Debt to Equity
0.29
Cash Flow Metrics
Revenue & Profitability Trend
Amrutanjan Health Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 4.5B | 4.2B | 3.8B | 4.0B | 3.3B |
Cost of Goods Sold | 2.2B | 2.1B | 1.8B | 1.8B | 1.4B |
Gross Profit | 2.3B | 2.1B | 2.0B | 2.2B | 1.9B |
Gross Margin % | 50.6% | 49.6% | 51.9% | 55.4% | 57.8% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 561.1M | 786.9M | 771.7M | 756.6M | 580.3M |
Other Operating Expenses | 552.0M | 222.6M | 185.8M | 96.6M | 52.0M |
Total Operating Expenses | 1.1B | 1.0B | 957.4M | 853.3M | 632.3M |
Operating Income | 516.7M | 480.2M | 420.6M | 819.7M | 795.0M |
Operating Margin % | 11.4% | 11.4% | 11.1% | 20.3% | 23.9% |
Non-Operating Items | |||||
Interest Income | - | 148.0M | 117.8M | 111.7M | 93.9M |
Interest Expense | 2.2M | 1.6M | 771.0K | 4.8M | 5.0M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 691.3M | 619.5M | 536.5M | 905.8M | 819.0M |
Income Tax | 183.0M | 169.7M | 138.1M | 233.9M | 207.1M |
Effective Tax Rate % | 26.5% | 27.4% | 25.7% | 25.8% | 25.3% |
Net Income | 508.3M | 449.7M | 398.3M | 671.9M | 611.9M |
Net Margin % | 11.3% | 10.7% | 10.5% | 16.6% | 18.4% |
Key Metrics | |||||
EBITDA | 758.8M | 689.2M | 591.8M | 970.3M | 939.7M |
EPS (Basic) | - | ₹15.50 | ₹13.65 | ₹23.00 | ₹20.94 |
EPS (Diluted) | - | ₹15.50 | ₹13.63 | ₹22.98 | ₹20.93 |
Basic Shares Outstanding | - | 29019920 | 29178398 | 29207609 | 29221922 |
Diluted Shares Outstanding | - | 29019920 | 29178398 | 29207609 | 29221922 |
Income Statement Trend
Amrutanjan Health Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 101.6M | 257.6M | 675.6M | 834.8M | 1.3B |
Short-term Investments | 1.9B | 1.8B | 1.2B | 1.2B | 446.4M |
Accounts Receivable | 558.2M | 478.9M | 330.2M | 382.6M | 176.6M |
Inventory | 272.6M | 289.0M | 288.3M | 260.0M | 174.6M |
Other Current Assets | 82.6M | 75.7M | 51.4M | 50.5M | 38.2M |
Total Current Assets | 2.9B | 3.0B | 2.6B | 2.7B | 2.2B |
Non-Current Assets | |||||
Property, Plant & Equipment | 477.3M | 27.2M | 24.0M | 17.7M | 7.4M |
Goodwill | 17.3M | 23.8M | 24.8M | 23.2M | 15.1M |
Intangible Assets | 17.3M | 23.8M | 24.8M | 23.2M | 15.1M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 176.5M | 17.1M | 15.4M | 19.2M | -100.0K |
Total Non-Current Assets | 1.3B | 711.9M | 1.0B | 752.2M | 513.7M |
Total Assets | 4.2B | 3.7B | 3.6B | 3.5B | 2.7B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 690.4M | 558.6M | 474.4M | 604.5M | 406.7M |
Short-term Debt | 4.0M | 3.3M | 5.1M | 5.7M | 6.4M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 94.5M | 84.0M | 78.5M | 65.0M | 48.6M |
Total Current Liabilities | 845.8M | 699.2M | 630.1M | 774.7M | 521.0M |
Non-Current Liabilities | |||||
Long-term Debt | 16.8M | 14.0M | 4.0M | 3.1M | 7.0M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | - | - | - | - | - |
Total Non-Current Liabilities | 101.9M | 84.6M | 83.1M | 72.7M | 66.0M |
Total Liabilities | 947.7M | 783.8M | 713.2M | 847.4M | 587.1M |
Equity | |||||
Common Stock | 28.9M | 28.9M | 29.2M | 29.2M | 29.2M |
Retained Earnings | - | 2.4B | 2.4B | 2.1B | 1.6B |
Treasury Stock | - | 16.2M | 44.6M | 45.0M | 9.6M |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 3.3B | 2.9B | 2.9B | 2.7B | 2.2B |
Key Metrics | |||||
Total Debt | 20.8M | 17.3M | 9.1M | 8.8M | 13.4M |
Working Capital | 2.1B | 2.3B | 2.0B | 2.0B | 1.7B |
Balance Sheet Composition
Amrutanjan Health Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 691.3M | 619.5M | 536.5M | 905.8M | 819.0M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 11.4M | 2.2M | 4.4M | -113.0K | 6.2M |
Working Capital Changes | -62.4M | -191.9M | 8.4M | -287.9M | 209.6M |
Operating Cash Flow | 482.1M | 282.8M | 432.2M | 510.9M | 945.9M |
Investing Activities | |||||
Capital Expenditures | -355.5M | -64.6M | -88.8M | -234.6M | -18.7M |
Acquisitions | - | - | - | - | - |
Investment Purchases | -114.6M | - | -123.2M | -302.1M | -915.3M |
Investment Sales | 5.0K | 115.0M | 75.0M | 48.2M | 0 |
Investing Cash Flow | -470.1M | 50.4M | -137.1M | -488.5M | -934.0M |
Financing Activities | |||||
Share Repurchases | 0 | -288.0M | 0 | - | -9.6M |
Dividends Paid | -132.7M | -133.9M | -144.1M | -124.8M | -57.8M |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | - |
Financing Cash Flow | -130.3M | -477.1M | -144.1M | -160.1M | -86.8M |
Free Cash Flow | 153.5M | 211.9M | 112.5M | 287.3M | 889.1M |
Net Change in Cash | -118.4M | -143.8M | 151.0M | -137.6M | -74.8M |
Cash Flow Trend
Amrutanjan Health Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
36.50
Price to Book
6.10
Price to Sales
4.16
Profitability Ratios
Profit Margin
11.37%
Operating Margin
7.36%
Return on Equity
15.56%
Return on Assets
12.06%
Financial Health
Current Ratio
3.44
Debt to Equity
0.64
Per Share Data
EPS (TTM)
₹18.88
Book Value per Share
₹112.98
Revenue per Share
₹165.76
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
amrutanjan | 19.9B | 36.50 | 6.10 | 15.56% | 11.37% | 0.64 |
Sun Pharmaceutical | 3.9T | 37.88 | 5.45 | 15.08% | 19.29% | 3.26 |
Divi's Laboratories | 1.6T | 70.42 | 10.88 | 14.64% | 23.89% | 0.03 |
Sun Pharma Advanced | 45.5B | -13.34 | -21.04 | 157.88% | -53.22% | -1.24 |
Aarti Drugs | 44.4B | 23.59 | 3.25 | 12.28% | 7.80% | 44.92 |
Sequent Scientific | 43.9B | 154.18 | 6.24 | 2.84% | 1.85% | 62.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.